Literature DB >> 2417065

Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine.

R L Momparler, J Bouchard, J Samson.   

Abstract

The effects of 5-AZA-2'-deoxycytidine (5-AZA-CdR) on the induction of morphological and biochemical differentiation and inhibition of DNA methylation of human HL-60 myeloid leukemic cells were investigated. 5-AZA-CdR at concentrations of 0.1-1 microgram ml-1 for 48-h exposure produced significant morphological differentiation of HL-60 leukemic cells to a more mature phenotype, augmented the cell surface marker (OKMI) for mature granulocytes/monocytes and also increased the superoxide anion production. Under these same conditions 5-AZA-CdR inhibited the synthesis of 5-methylcytosine in DNA suggesting that there is a correlation between the induction of differentiation and inhibition of DNA methylation. At concentrations of 5-AZA-CdR that inhibit DNA methylation there was a marked decrease in colony-formation suggesting that the antileukemic action of this analog is related to the methylation of DNA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2417065     DOI: 10.1016/0145-2126(85)90123-7

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes.

Authors:  Joanna Edyta Fraczek; Mathieu Vinken; Dirk Tourwé; Tamara Vanhaecke; Vera Rogiers
Journal:  Invest New Drugs       Date:  2011-03-29       Impact factor: 3.850

2.  Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.

Authors:  Elias Jabbour; Sergio Giralt; Hagop Kantarjian; Guillermo Garcia-Manero; Madan Jagasia; Partow Kebriaei; Leandro de Padua; Elizabeth J Shpall; Richard Champlin; Marcos de Lima
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

3.  The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Authors:  Maria Nieto; Pierre Demolis; Eliane Béhanzin; Alexandre Moreau; Ian Hudson; Beatriz Flores; Henry Stemplewski; Tomas Salmonson; Christian Gisselbrecht; David Bowen; Francesco Pignatti
Journal:  Oncologist       Date:  2016-04-18

Review 4.  Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.

Authors:  Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

5.  Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.

Authors:  R L Momparler; L F Momparler
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.

Authors:  R Jüttermann; E Li; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

7.  Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.

Authors:  Metin Karahoca; Richard L Momparler
Journal:  Clin Epigenetics       Date:  2013-02-01       Impact factor: 6.551

8.  Granulocyte heterochromatin: defining the epigenome.

Authors:  Donald E Olins; Ada L Olins
Journal:  BMC Cell Biol       Date:  2005-11-15       Impact factor: 4.241

9.  All-trans retinoic acid enhances the effect of 5-aza-2'-deoxycytidine on p16INK4a demethylation, and the two drugs synergistically activate retinoic acid receptor β gene expression in the human erythroleukemia K562 cell line.

Authors:  Lili Xiang; Weimin Dong; Rong Wang; Jiang Wei; Guoqiang Qiu; Jiannong Cen; Zixing Chen; Xiao Zheng; Shaoyan Hu; Xiaobao Xie; Xiangshan Cao; Weiying Gu
Journal:  Oncol Lett       Date:  2014-05-12       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.